EpiPen Price Gouging No Better


The EpiPen has been around for decades—the device, known as an autoinjector was acquired by Mylan Pharmaceuticals (NASDAQ: MYL) in 2007, and cost about $57 each at that time. Today, EpiPens cost $609 for a twin-pack, with each device delivering $1-worth of epinephrine to combat life-threatening allergic reactions, and by 2015 sales of EpiPen represented 40% of Mylan’s profits.

Mylan has increased the list price of 17 times despite widespread media coverage, consumer complaints, and congressional inquiries that labeled its business practices “disgusting” and “disgraceful.” Now, a class-action lawsuit is claiming that Mylan is guilty of violations of consumer protection laws and the Racketeer Influenced and Corrupt Organizations Act.

The suit claims that the “skyrocketing” list price of EpiPen is the result of Mylan’s payments of rebates to pharmacy benefits managers, including CVS, Caremark, Express Scripts and Optum Rx. The suit claims that both sides had an interest in driving up the price and that competing devices never has a chance, because they could not or would not pay the same level of rebates that Mylan was paying.

Mylan blames a broken health care system full of inefficiencies for the high prices that plague consumers. The PBMs meanwhile, speaking through their trade organization, have said, “Mylan has spent the past year blaming Washington, the prescription drug supply chain, and competitors for its unusual pricing practices. It’s time for them to look in the mirror and take responsibility.”

Profiteering at the Expense of Sick Children and Adults

We live in a world of market realities. Drugmakers like Mylan should be able to “do good and do well” as their CEO has said. But the market is also vulnerable to collusion and other forces that allow price gouging, as the lawsuit against them suggests. And if the racketeering charges weren’t bad enough, regulators recently revealed that Mylan had likely overcharged Medicaid by $1.27 billion for EpiPens.

When does profit become profiteering?

What about Mylan’s online coupons, which shifts the inflated cost of EpiPen to insurers and self-funded employer plans?

What should regulators do about the fact that Mylan has an effective monopoly on a lifesaving product, which allows the company to play “rope-a-dope” (as Georgia Representative Elijah Cummings put it) with all the bad press and move on without making any changes?

We’ve put together some sources below for further reading. In the meantime, for parents of sick children, the options are limited. EpiPens have an expiration of one year, which means that if the patient doesn’t have a life-threatening allergic reaction in a given year (obviously a good thing), they are out of pocket yet again—hundreds of dollars for a device that delivers just $1 worth of drug.

Read Charles Duhigg’s excellent column in the New York Times here:

“Outcry Over EpiPen Prices Hasn’t Made Them Any Lower”

Read about the congressional hearings here:

“5 things we learned from EpiPen price hike hearings”

Read about the racketeering suit filed against Mylan here: 

“Mylan hit with racketeering suit over big price hikes of EpiPen”

Read Emily Willingham’s excellent analysis of Mylan’s marketing in Forbes: 

“Why Did Mylan Hike EpiPen Prices 400%? Because They Could”


40 Grove St, Suite 270 Wellesley, MA 02482

  • LinkedIn - White Circle
  • Facebook - White Circle
  • Twitter - White Circle
  • YouTube - White Circle


© Copyright 2020 Scripta Insights, Inc. 

Scripta™ is neither a pharmacy nor a doctor. The benefit service does not tell you what drug to take and does not participate in the drug selection process. Only your physician can determine the medications that are right for you. These alternative medications are options for less costly drugs that physicians may prescribe in place of the medications you are taking now. Scripta has reviewed your current medications only for the purpose of identifying potential cost savings for you to consider with your physician. Scripta has not analyzed the effectiveness or other therapeutic aspects of these medication alternatives. Accordingly, this report and any other forms of communication received from Scripta are not, nor should they be interpreted as, any form of treatment, drug regimen review, or provision of counseling or consultation by a prescriber, pharmacist or pharmacy. Do not stop taking your medication, change your medication, or start taking a new medication without being directed to do so by your physician and filling the prescription under the oversight of a licensed pharmacist. The alternatives set forth above may not be equivalent to your current medication, may interact adversely with your other medications, may not be indicated in light of your other conditions, may cause different or severe side effects, or may be less effective at treating your condition. Medication prices are approximate based on information provided by your pharmacy benefits manager, insurance plans, and/or employer, and may vary from pharmacy to pharmacy. Check with your insurance plan to obtain a full list of pharmacies where your prescriptions can be filled. All information herein is HIPAA protected, treated as highly confidential, and never shared with your employer.

Scripta™, Scripta Insights™ and The Best Meds at the Best Price® are registered trademarks of Scripta Insights, Inc. The contents of the site are for informational purposes only and not intended as a substitute for professional medical advice, diagnosis, or treatment. We do not recommend or endorse any specific prescription drug or pharmacy that may be mentioned herein. Reliance on any information provided by us, our affiliates, employees or others is solely at your own risk.